Crystal PharmaTech Collaborates with Freeslate for Solid Form Screening - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Crystal PharmaTech Collaborates with Freeslate for Solid Form Screening

Crystal Pharmatech, a leader in solid-state chemistry services for drug development, has selected Freeslate, a provider of high through put research solutions, for its CM Protégé PharmD System for polymorph, salt, co-crystal, and solubility screens of APIs.

The Freeslate PharmD System will be used to extend thepolymorph and solubility screens completed without increasing the time or resources required. Crystal Pharmatech will also serve as a reference site and demo lab for Freeslate, hosting customers and product demonstrations and participating in speaking engagements.

Freeslate's CM Protégé PharmD System brings high-throughput solid and solubility screening to a broader range of researchers with a fully automated platform. The system can evaluate up to 384 crystallization conditions per run to quickly turn around solid-form screening projects and save users valuable material through its ability to use approximately 1 g of API per solid-form screen. Solid forms can be analyzed by birefringence, x-ray powder diffraction, and Raman spectroscopy directly from the glass universal substrate without any manual manipulation of fragile crystals. Other analyses and experiments, such as solid form stability, can also be conducted directly on the glass universal substrate. Heating, cooling, and mixing on-deck allows for simultaneous slurry, precipitation, cooling, and evaporation experiments on a single platform.

The CM Protégé PharmD System uses Freeslate's Lab Execution and Analysis (LEA) software for library design, protocol development/execution, data analysis, and reporting. This allows users to design complex experiments quickly using its recipe-oriented approach. Using LEA, experimental conditions can be linked to analytical data for easy viewing and reporting.

Source: Crystal Pharmatech


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here